Science
What Powers ProteinQure?
We use game-changing technology and science to engineer new treatments for disease.
Using machine learning and distributed computing, computational biophysics and structure-based drug design, our advanced tools are helping us to create novel therapeutics to address unmet medical need.
Dare To
Deliver
Deliver
Peptide Drug Conjugates
Peptide-drug conjugates (PDCs) mark a significant leap forward in developing therapies that are both highly targeted and exceptionally effective. A PDC is composed of three essential components:
Payload
What exerts the desired therapeutic effect.
Linker
Connects the peptide to the drug, ensuring stability and optimal payload release.
Therapeutic Peptide
This guides the drug to the target site.
PDCs vS ADCs
Next-Generation Drug-Conjugates
While many are familiar with the success of Antibody Drug Conjugates (ADCs) in targeted cancer therapies, PDCs are emerging as promising alternatives, boasting several advantages: PDCs are significantly smaller, allowing for better tissue penetration. This could provide more effective delivery of the therapeutic payload to a tumor microenvironment, for instance.
The synthesis of peptides can also be more cost-effective and less complex than that of antibodies, making PDCs a more accessible option for widespread clinical development. Additionally, PDCs exhibit lower immunogenicity, reducing the risk of adverse responses.
In-silico
Design
Design
ProteinStudio™
ProteinQure leverages cutting-edge computational biophysics and structure-based drug design to explore the vast potential of PDCs. We focus on designing conjugates with peptides and linkers that have been computationally optimized to target a specific type of cell surface receptor.
ProteinStudio™ redefines the boundaries of drug discovery by leveraging the full potential of the chemical space of thousands of non-natural amino acids and capping groups. With a foundation in computational biology, chemistry, and machine learning, it integrates multi-objective optimization algorithms and custom-trained AI models with advanced molecular simulations to optimize peptides and linkers.
Unparalleled in computing power, ProteinStudioTM operates on a petascale, enabling the exploration of vast peptide libraries, and the design of peptides consisting of a mix of natural and non-natural amino acids and exotic chemistries. The platform is engineered for scalability and modularity, surpassing conventional solutions with its ability to support extensive compute jobs and cross-software workflows.
Title Needed
Structure driven
At the heart of our approach lies a profound reliance on and expertise in utilizing 3D protein structures. This is the cornerstone of our structure-driven methodology. Our ability to model and study these structures in-silico enables us to navigate the complex landscape of protein dynamics and protein-protein interactions
By leveraging detailed structural insights, we achieve precision in predicting molecular interactions and properties, enabling the creation of innovative therapeutics. Our expertise in computational biology and molecular modeling underscores our commitment to advancing drug development through scientifically sound and groundbreaking designs.
ML
Cutting-Edge Machine Learning
Our custom machine learning (ML) algorithms are trained on enriched datasets that include public, proprietary, and often project-specific customer data. We leverage innovative architectures and proprietary peptide representations to create our own proprietary library of sequence- and structure-based ML models. These models, designed to fully support thousands of non-canonical amino acids (NCAAs), set new standards in data-driven peptide design.
The computational prowess of ProteinStudioTM is instrumental in predicting key properties like affinity, solubility, specificity, and functional outcomes, paving the way for new therapeutic possibilities.
By combining molecular design and optimization on supercomputers with in-house wetlab experiments, we accelerate the journey from conceptual scaffolds to clinically relevant peptide- drug conjugates, marking a new era in precision medicine and drug development.
DIVE DEEP
LEARN MORE ABOUT PQ203, OUR MOST PROMISING THERAPEUTIC AGAINST TRIPLE-NEGATIVE BREAST CANCER.
Read More
Check out this scientific paper that gives background on our focus area.
Help Cures
DONATE TO THE CANADIAN CANCER SOCIETY TO SUPPORT RESEARCH ACROSS VARIOUS CANCER TYPES.